相关实验视频

Updated: Jun 8, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

在非小细胞肺癌中预测性[F]-FDG PET/CT 基射基因组学对驱动基因突变的建模

Ricarda Hinzpeter¹, Roshini Kulanthaivelu¹, Andres Kohan¹

¹University Medical Imaging Toronto, Toronto Joint Department Medical Imaging, University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, M5G 2N2, Toronto, Ontario, Canada (R.H., R.K., A.K., V.M., S.A.M., C.O., U.M., M.M., P.V.H.).

Academic radiology

|July 13, 2024

概括

[18F]-FDG PET/CT扫描中的放射性数据显示,与非小细胞肺癌 (NSCLC) 的驱动基因突变存在中等到良好的相关性. 结合PET/CT放射学可以提高NSCLC患者基因组概况的预测.

科学领域:

在瘤学瘤学.
放射学放射学是一门学科.
基因组学就是基因组学.

背景情况:

非小细胞肺癌 (NSCLC) 是癌症相关死亡的主要原因.
驱动基因突变显著影响NSCLC的进展和治疗反应.
对基因组资料的准确预测对于个性化NSCLC治疗至关重要.

研究的目的:

调查从[¹⁸F]-FDG PET/CT成像和NSCLC中驱动基因突变中获得的放射学特征之间的相关性.
评估放射学在识别NSCLC中的特定遗传变化的预测能力.
探索PET/CT放射学组合在NSCLC中增强基因组分析的实用性.

主要方法:

对128名经过手术治疗的NSCLC患者进行回顾性分析,这些患者接受了手术前[F]-FDG PET/CT和基因组分析.
使用LIFEx软件从PET/CT图像中进行半自动细分和特征提取.
对驱动基因突变 (TP53,KRAS,EGFR) 的放射学特征和下一代测序 (NGS) 数据之间的相关性分析.

主要成果:

超过一半的NSCLC瘤 (53%) 携带三种或更多的基因突变.
在55%的样本中存在TP53突变,在26%的样本中存在KRAS,在17%的样本中存在EGFR.
放射学特征对驱动基因突变具有中等到良好的预测能力,PET/CT特征组合显示TP53.3的最高预测值.

结论:

[¹⁸F]-FDG PET/CT衍生放射学与NSCLC中的驱动基因突变具有中等到良好的相关性.
结合PET/CT放射学特征提高了NSCLC基因组分析的预测能力.
放射学分析对预测NSCLC分子亚型的非侵入性预测具有前景.

关键词:

德国联邦航空公司 (FDG)基因组学就是基因组学.非小细胞肺癌是非小细胞肺癌.聚乙烯/聚乙烯/聚乙烯无线电学 (Radiomics) 是一种辐射学.

更多相关视频

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...